Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
22 Clinical Trials near Milwaukee, WI
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
VGA039 for Von Willebrand Disease
Milwaukee, WisconsinThis trial tests VGA039, a new drug, in healthy people and those with Von Willebrand disease. The goal is to see if it is safe and how it behaves in the body when injected. Participants will be monitored for a period of time after receiving the drug.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:12 - 60
Sex:All
116 Participants Needed
FrontlineODP™ Spray Dried Plasma for Blood Clotting Disorders
Milwaukee, WisconsinThis study in healthy volunteers is designed to assess the safety of infusing increasing doses of spray dried plasma (FrontlineODP).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 65
Sex:All
24 Participants Needed
Brain Imaging for Concussion in Former NFL Players
Milwaukee, WisconsinThe purpose of this 5-year prospective research study is to characterize the association between concussions, sub-concussive exposure, and long-term neurologic health outcomes in former NFL players. To achieve the study aims, the investigators will conduct detailed research visits that include clinical outcome assessments, blood-based biomarkers, advanced magnetic resonance imaging (MRI), positron emission tomography (PET) using investigational tracers and genetic testing. Ultimately, the goal of this study is to translate the findings from this study into clinical, interventional studies for at risk former NFL players.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 1
Age:50 - 70
Sex:Male
250 Participants Needed
Experimental Drug for Leukemia Post-Stem Cell Transplant
Milwaukee, WisconsinThis is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Active Cardiac Disease, Significant Infection, Prior HCT, Others
63 Participants Needed
BMS-984923 for Drug Interaction
West Bend, WisconsinThe goal of this study is to learn if the investigational drug, BMS-984923 will impact the exposure and clearance of other medications when given together. Most drugs are broken down and cleared in the body via cytochrome P450 enzymes in the liver. The metabolism and clearance of certain drugs can be affected by other drugs when dosed together. To evaluate the impact of BMS-984923 on the clearance of other medications, we will investigate three known pathways which may be impacted by BMS-984923.
In this study participants will take one dose of the three known medications, midazolam, caffeine and dextromethorphan together. These drugs are known to be cleared by different cytochrome P450 enzymes. Blood will be collected to evaluate the exposure and clearance of these medications and their primary metabolites. Study participants will then be administered BMS-984923 for 18-days. On the 18th Day of BMS-984923 dosing, participants will again be co-administering midazolam, caffeine and dextromethorphan. Blood will be collected again, and the concentration of each drug will be measured. We will learn in this study if BMS-984923 changes the exposure and metabolism of the known drugs. These results will inform how BMS-984923 can be administered to patients who take multiple medications.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 50
Sex:All
36 Participants Needed
ARN-75039 for Lassa Fever
West Bend, WisconsinThis trial tests a new oral drug called ARN-75039 in healthy adults to see if it's safe and how the body handles it. Researchers will measure how much of the drug enters the bloodstream, how long it stays there, and how it's broken down and eliminated.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:All
Key Eligibility Criteria
Disqualifiers:HIV, Drug Abuse, Malignancy, Others
Must Not Be Taking:OTC Medications, Herbal Medications
64 Participants Needed
Advil Dual Action for Pain
West Bend, WisconsinThe primary purpose of this study is to demonstrate the bioequivalence of new formulation Advil Dual Action (ADA) liquid filled capsules (Test) compared to the currently marketed ADA Caplet (Reference) under fasted conditions and to assess the relative bioavailability of ADA liquid filled capsules (Test) under fed conditions compared to ADA liquid filled capsules (Reference) under fasted conditions.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Breastfeeding, Asthma, Others
Must Not Be Taking:Anticonvulsants, Herbal Remedies
54 Participants Needed
SAR444881 + Standard Therapies for Advanced Cancer
Zion, IllinoisThis trial tests a new drug, SAR444881, alone and with other treatments in advanced cancer patients who haven't responded to other therapies. The goal is to find the best dose and combination to treat these patients effectively.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
456 Participants Needed
C. difficile Vaccine for C. difficile Infection
Gurnee, IllinoisAn antibody is a substance your body makes to fight off infection. This study will explore the safety and antibody response of a vaccine to prevent severe diarrhea caused by a germ called Clostridoides difficile (C. diff). Three new formulations of the C. diff vaccine will be used in this study, in addition to a C. diff vaccine formulation that has been studied in previous clinical trials.
The purpose of this study is to understand if giving the new C. diff vaccine formulations helps people make as many antibodies as giving the previously studied C. diff vaccine formulation.
The study is divided into 2 phases.
Phase 1 will evaluate 3 new formulations of the C. diff vaccine and 2 dosing schedules spread out over 2 months or 6 months.
The Phase 1 portion of the study is seeking participants:
* who are healthy adults of 65 to 84 years of age
* who have not had a C. diff infection before
* who have not received a C. diff vaccine or C. diff monoclonal antibody therapy before.
All participants in Phase 1 will receive study injections with active vaccine or placebo at each vaccination visit, depending on the vaccine group to which they are assigned. A placebo does not contain any active ingredients. Participants in Phase 1 will attend at least 9 study visits and will take part in the study for approximately 18 months. Based on the results of Phase 1, 1 or 2 of the new C. diff vaccine formulations will be chosen for further study in Phase 2.
Phase 2 will evaluate the safety and effects of the new C. diff vaccine formulation(s) chosen in Phase 1.
The Phase 2 portion of the study is seeking participants:
* who are healthy adults ≥65 years of age
* who have not had a C. diff infection before
* who have not received a C. diff vaccine or C. diff monoclonal antibody therapy before.
Phase 2 participants will receive active C. diff vaccine or placebo at each vaccination visit. Participants in Phase 2 will attend at least 6 and up to 12 study visits and will take part in the study for up to 4 years.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:65 - 84
Sex:All
689 Participants Needed
Tavapadon Bioavailability Study
Grayslake, IllinoisThis study will assess the relative bioavailability of two different Oral formulations of tavapadon in healthy adult participants.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:All
84 Participants Needed
ABBV-701 for Healthy Subjects
Grayslake, IllinoisThe main objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous (SC) ABBV-701 in healthy adult western and Asian participants.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 60
Sex:All
58 Participants Needed
ABBV-932 for Healthy Subjects
Grayslake, IllinoisThis study will assess the relative bioavailability and effect of food on pharmacokinetics of ABBV-932 oral administration in healthy adult participants.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Epilepsy, Cardiac, Respiratory, Others
28 Participants Needed
ABBV-142 for Healthy Subjects
Grayslake, IllinoisThis study is designed to assess the pharmacokinetic properties, safety, tolerability, and immunogenicity of ABBV-142 and determine whether predicted efficacious exposures can be safely achieved in humans.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:All
Key Eligibility Criteria
Disqualifiers:Significant Illness, Tobacco, Drug Abuse, Others
74 Participants Needed
Venetoclax for Healthy Subjects
Grayslake, IllinoisThe objective of this study is to assess the bioavailability (BA) of venetoclax new high drug load hot melt extrusion-03 (HME-03) tablet formulation at two different tablet strengths relative to the commercial venetoclax tablet formulation under high-fat conditions in healthy female volunteers. Additionally, this study will assess the potential food effect on the BA of the venetoclax HME-03 tablet at the highest dosage strength.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 65
Sex:Female
Key Eligibility Criteria
Disqualifiers:Renal, Neurologic, Psychiatric, Others
72 Participants Needed
ABBV-CLS-616 for Healthy Volunteers
Grayslake, IllinoisThis is a Phase 1, first in human, randomized, four-part study to investigate the safety, tolerability, and pharmacokinetics of ABBV-CLS-616 after oral dosing in healthy volunteers.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Ocular Disease, Neurological Epilepsy, Cardiac, Others
112 Participants Needed
ABBV-722 Safety Study in Healthy Adults
Grayslake, IllinoisThis is a Phase 1, first-in-human study to investigate safety, tolerability, and pharmacokinetics of ABBV-722 after oral dosing in healthy adult participants.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Recent Illness, Alcohol, Tobacco, Others
88 Participants Needed
ABBV-1088 for Healthy Subjects
Grayslake, IllinoisThis study will assess the safety, tolerability, and pharmacokinetics of ABBV-1088 in healthy adult Western, Han-Chinese and Japanese participants. This study will also assess drug-drug interaction between itraconazole and ABBV-1088 in healthy adult Western participants.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Neurological, Respiratory, Endocrine, Others
66 Participants Needed
Risankizumab for Healthy Subjects
Grayslake, IllinoisThis study will assess the pharmacokinetics, relative bioavailability and tolerability of two formulations of risankizumab following subcutaneous (SC) administration in healthy adult participants.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 60
Sex:All
231 Participants Needed
Drug Interaction Study in Healthy Subjects
Grayslake, IllinoisThis study is to assess the change of itraconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety, and tolerability of a single dose of icalcaprant in healthy participants.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:All
12 Participants Needed
Risankizumab for Healthy Participants
Grayslake, IllinoisThe objective of this study is to compare pharmacokinetic exposures following intravenous and subcutaneous administration of Risankizumab.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 65
Sex:All
60 Participants Needed
ABBV-141 for Healthy Adults
Grayslake, IllinoisThe purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and immunogenicity after single ascending doses (SAD) of ABBV-141 in healthy adult Western and Asian participants.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:All
99 Participants Needed
ABBV-932 for Generalized Anxiety Disorder
Grayslake, IllinoisThis trial tests a new medication called ABBV-932 to see how it works in the body and if it is safe for healthy adults and those with anxiety or bipolar disorder.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 65
Sex:All
72 Participants Needed
Page 1 of 1+
Frequently Asked Questions
How much do clinical trials in Milwaukee, WI pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do clinical trials in Milwaukee, WI work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Milwaukee, WI 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Milwaukee, WI is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Milwaukee, WI several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a medical study in Milwaukee, WI ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest clinical trials in Milwaukee, WI ?
Most recently, we added ABBV-701 for Healthy Subjects, Tavapadon Bioavailability Study and ABBV-932 for Healthy Subjects to the Power online platform.